. 2021 Apr 30;2021(1):e202103. doi: 10.21542/gcsp.2021.3

Table 3. Univariable comparison for patients with or without hemopericardium.

Variables	Patients had Hemopericardium, N = 4	Patients without Hemopericardium, N = 40	P value
Age, years	77.8 ± 12.8	61.8 ± 12.5	0.019
BMI, kg/m²	28.0 ± 5.2	28.6 ± 4.0	0.822
Male gender, n (%)	3 (75.0%)	35 (87.5%)	0.487
Hypertension, n (%)	0 (0%)	19 (47.4%)	0.067
Diabetes, n (%)	0 (0%)	8 (20.0%)	0.323
CAD, n (%)	0 (0%)	15 (37.5%)	0.131
HF, n (%)	4 (100%)	38 (95.0%)	0.647
NYHA classification,	3.0 ± 0	2.4 ± 0.8	0.181
CKD, n (%)	2 (50.0%)	9 (22.5%)	0.226
CKD classification,	1.5 ± 1.7	0.6 ± 1.1	0.114
AF, n (%)	3 (75.0%)	13 (32.5%)	0.092
ICM, n (%)	0 (0%)	11 (27.5%)	0.226
DCM, n (%)	3 (75.0%)	15 (37.5%)	0.146
HCM, n (%)	1 (25.0%)	2 (5.0%)	0.130
ARVC, n (%)	0 (0%)	5 (12.5%)	0.453
Vavular heart disease, n (%)	0 (0%)	1 (2.5%)	0.749
Beta-Blocker, n (%)	4 (100%)	33 (82.5%)	0.362
Amiodarone, n (%)	4 (100%)	26 (65.0%)	0.152
ACEI/ARB, n (%)	3 (75%)	19 (47.5%)	0.294
Spirolactone, n (%)	2 (50%)	13 (32.5%)	0.481
OACs, n (%)	3 (75.0%)	13 (32.5%)	0.129
VA origin form LV, n (%)	4 (100%)	29 (76.3%)	0.272
VT cycle length, ms	330.0 ± 60.0	319.4 ± 54.1	0.723
LVEED, mm	58.8 ± 9.1	57.9 ± 7.9	0.849
LVEF, %	37.5 ± 13.2	41.8 ± 12.9	0.539
Acute success, n (%)	3 (75.0%)	32 (80.0%)	0.267
Procedure time, min	207.5 ± 15.0	157.8 ± 52.7	0.07
Fluoroscopic time, min	21.2 ± 1.8	18.2 ± 8.8	0.508
Hospital stay, day	16.3 ± 10.4	4.3 ± 2.3	<0.01
In-hospital VT recurrence, n (%)	1 (25.0%)	5 (15.1%)	0.62
12-month VT recurrence, n (%)	3 (75.0%)	12 (36.4%)	0.17

Notes.